Gabrielle examines why ultra‐wealthy investors often bypass longevity science, analyzing perceived scientific uncertainties, cultural perceptions of aging, and philanthropic norms to shed light on funding gaps.

Key points

• Perception of aging as immutable leads many billionaires to prioritize traditional philanthropy over longevity research.
• High financial risks and long development timelines discourage investment in life‐extension technologies.
• Ethical concerns and legacy preferences further limit early funding for interventions targeting aging processes.

Why it matters: Unearthing barriers to funding longevity research is vital to mobilize capital towards breakthroughs that extend healthy human lifespan.